文献速递消化系统肿瘤支持与姑息治疗

补锌降低瑞戈非尼所致≥2级手足皮肤反应发生率:一项II期随机临床试验

Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
PubMed 文献 · Eur J Cancer · 2023-11-13

这项II期随机临床试验(NCT03898102)旨在探讨补锌能否减轻瑞戈非尼治疗前8周内所致手足皮肤反应(HFSR)的严重程度。瑞戈非尼为口服多激酶抑制剂,获批用于转移性结直肠癌(mCRC),常引起HFSR;血管内皮生长因子受体-酪氨酸激酶抑制剂(VEGFR-TKI)治疗时HFSR总体发生率约35%。

要点

  • 瑞戈非尼靶向VEGFR 1-3、PDGFR、cKIT、BRAF和RET,获批用于转移性结直肠癌,常引起手足皮肤反应。
  • VEGFR-TKI治疗时手足皮肤反应总体发生率约35%。
  • 该II期随机试验评估补锌能否降低瑞戈非尼治疗前8周内手足皮肤反应的严重程度。

核心结论

  • 补锌可降低瑞戈非尼所致≥2级手足皮肤反应的发生率,该结论来自一项II期随机临床试验。

研究设计与样本

  • II期随机临床试验(NCT03898102),旨在评估补锌能否减轻瑞戈非尼治疗前8周内所致手足皮肤反应的严重程度。

主要发现

  • VEGFR-TKI治疗时手足皮肤反应总体发生率约35%;瑞戈非尼常引起手足皮肤反应。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To the editor: Hand-foot skin reaction (HFSR), characterized by skin abnormalities on palmoplantar surfaces, has an overall incidence of about 35% upon vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) treatment.1 Zinc, which plays a role in maintaining skin health, may be implicated in the pathogenesis of HFSR.2 Zinc deficiency has been shown to associate with dermatological toxicities of epidermal growth factor receptor (EGFR)-TKI.3, 4 Regorafenib, an oral multi-kinase inhibitor targeting VEGFR 1-3, PDGFR, cKIT, BRAF, and RET1, is approved for the treatment of metastatic colorectal cancer (mCRC) but commonly causes HFSR.5 This phase II randomized trial aimed to investigate whether zinc supplementation can reduce the severity of HFSR induced by regorafenib within the first 8 weeks of treatment (NCT03898102).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Huang WK, Hsu HC, Yang TS, et al. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial. Eur J Cancer. 2023. PMID: 37968194. doi:10.1016/j.ejca.2023.113286

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。